 VICTORIA, British Columbia--BUSINESS WIRE--- IPA POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. the Company or IPA NASDAQ: IPA TSX VENTURE: IPA today announced new results from its TATX-03 PolyTopeTM Therapy, a four monoclonal antibody cocktail developed for the potential prevention and treatment of SARS-CoV-2, demonstrating potent pseudovirus neutralizing activity against the SARS-CoV-2 Delta B.1.617.2 variant. The Company anticipated viral evolution leading to novel SARS-CoV-2 variants of concern throu 